Results 241 to 250 of about 927,276 (294)
Some of the next articles are maybe not open access.
Endogenous angiogenesis inhibitors
Apmis, 2004When the FDA commissioner announced in February 2004 the approval of Avastin for the treatment of patients with colon cancer, he called angiogenesis inhibitors a fourth modality of anti‐cancer therapy. Because angiogenesis inhibitors are relatively less toxic than conventional chemotherapy and have a lower risk of drug resistance, they may also ...
exaly +3 more sources
Src Inhibitors and Angiogenesis
Current Pharmaceutical Design, 2007 Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels in limited physiological conditions, and can also occur under pathological situations as retinopathies, arthritis, endometriosis and cancer. Enhanced angiogenesis is present in tumors that need new blood capillaries to grow, remove metabolic waste and transport
SCHENONE S +2 more
openaire +6 more sources
Endogenous angiogenesis inhibitors and their therapeutic implications
International Journal of Biochemistry and Cell Biology, 2001 A number of endogenous inhibitors targeting the tumor vasculature have recently been identified using in vitro and in vivo antiangiogenesis models. While many of these angiogenesis inhibitors display a broad spectrum of biological actions on several ...
Yihai Cao
exaly +2 more sources
Clinical and Translational Oncology, 2006
Angiogenesis and neovascularization are important mechanisms for tumor growth, progression and, subsequent metastasis. Cancer cells, as part of an inflammatory process, produce and induce multiple molecules (proangiogenic and antiangiogenic) from the surrounding stromal cells. Vascular Endothelial Growth Factor (VEGF) is the most relevant proangiogenic
V, Almendro, P, Gascón
openaire +2 more sources
Angiogenesis and neovascularization are important mechanisms for tumor growth, progression and, subsequent metastasis. Cancer cells, as part of an inflammatory process, produce and induce multiple molecules (proangiogenic and antiangiogenic) from the surrounding stromal cells. Vascular Endothelial Growth Factor (VEGF) is the most relevant proangiogenic
V, Almendro, P, Gascón
openaire +2 more sources
Current Oncology Reports, 2000
Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block ...
T R, Tennant +2 more
openaire +2 more sources
Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block ...
T R, Tennant +2 more
openaire +2 more sources
Nature Biotechnology, 1991
Angiogenesis, the formation of new capillaries, is essential to a number of important physiological events, both normal and pathological. Recently, increased attention has focused on the purification and characterization of inhibitors of this process, because of the potential therapeutic value of angiogenesis inhibitors in controlling such "angiogenic ...
M A, Moses, R, Langer
openaire +2 more sources
Angiogenesis, the formation of new capillaries, is essential to a number of important physiological events, both normal and pathological. Recently, increased attention has focused on the purification and characterization of inhibitors of this process, because of the potential therapeutic value of angiogenesis inhibitors in controlling such "angiogenic ...
M A, Moses, R, Langer
openaire +2 more sources
2015
Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for therapeutic purposes.
H, Büning, U T, Hacker
openaire +2 more sources
Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for therapeutic purposes.
H, Büning, U T, Hacker
openaire +2 more sources
Update on angiogenesis inhibitors
Current Opinion in Oncology, 2005A number of therapeutic agents have been developed which have anti-angiogenic potential. Here we present the most recent data from clinical trials with some of the promising inhibitors of angiogenesis.Agents that target the vascular endothelial growth factor signaling pathway are the furthest along in clinical development.
Anaadriana, Zakarija, Gerald, Soff
openaire +2 more sources
Maspin is an angiogenesis inhibitor
Nature Medicine, 2000Maspin, a unique member of the serpin family, is a secreted protein encoded by a class II tumor suppressor gene whose downregulation is associated with the development of breast and prostate cancers. Overexpression of maspin in breast tumor cells limits their growth and metastases in vivo.
M, Zhang, O, Volpert, Y H, Shi, N, Bouck
openaire +2 more sources
Protamine is an inhibitor of angiogenesis
Nature, 1982Protamine is shown to be a specific inhibitor of angiogenesis. The compound inhibits the capillary proliferation observed in embryogenesis, inflammation, certain immune reactions and the growth of solid tumours.
S, Taylor, J, Folkman
openaire +2 more sources